Lotus Pharmaceutical Co., Ltd.
TWSE:1795.TW
282 (TWD) • At close November 14, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) TWD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 16,957.971 | 14,632.772 | 12,649.189 | 10,728.583 | 9,174.74 | 6,428.894 | 6,423.76 | 5,902.566 | 5,521.937 | 2,310.021 | 658.481 | 503.153 | 532.209 | 590.184 | 606.822 |
| Cost of Revenue
| 8,618.928 | 6,826.623 | 7,009.069 | 6,131.96 | 4,926.869 | 3,289.414 | 3,344.086 | 2,574.537 | 2,293.149 | 1,155.215 | 249.399 | 228.216 | 204.711 | 235.66 | 248.426 |
| Gross Profit
| 8,339.043 | 7,806.149 | 5,640.12 | 4,596.623 | 4,247.871 | 3,139.48 | 3,079.674 | 3,328.029 | 3,228.788 | 1,154.806 | 409.082 | 274.937 | 327.498 | 354.524 | 358.396 |
| Gross Profit Ratio
| 0.492 | 0.533 | 0.446 | 0.428 | 0.463 | 0.488 | 0.479 | 0.564 | 0.585 | 0.5 | 0.621 | 0.546 | 0.615 | 0.601 | 0.591 |
| Reseach & Development Expenses
| 720.826 | 520.449 | 595.925 | 505.379 | 553.569 | 324.936 | 329.523 | 452.175 | 298.721 | 131.973 | 190.227 | 231.932 | 237.917 | 96.798 | 93.908 |
| General & Administrative Expenses
| 1,224.068 | 1,053.255 | 905.783 | 904.969 | 787.073 | 681.609 | 680.452 | 726.739 | 637.655 | 1,230.5 | 71.301 | 68.941 | 52.747 | 61.594 | 51.909 |
| Selling & Marketing Expenses
| 2,540.013 | 2,124.665 | 1,808.748 | 1,574.276 | 1,793.609 | 1,684.247 | 1,546.61 | 1,904.732 | 1,843.573 | 227.584 | 172.845 | 177.472 | 182.699 | 173.37 | 172.204 |
| SG&A
| 3,760.044 | 3,177.92 | 2,714.531 | 2,479.245 | 2,580.682 | 2,365.856 | 2,227.062 | 2,631.471 | 2,481.228 | 1,458.084 | 244.146 | 246.413 | 235.446 | 234.964 | 224.113 |
| Other Expenses
| 0 | 208.05 | -133.913 | 17.811 | 102.767 | 34.741 | -52.529 | 52.864 | 214.875 | -64.766 | 53.934 | 26.011 | 62.011 | 17.904 | -12.614 |
| Operating Expenses
| 4,480.87 | 3,698.369 | 3,310.456 | 2,984.624 | 3,134.251 | 2,690.792 | 2,556.585 | 3,083.646 | 2,779.949 | 1,590.057 | 434.373 | 478.345 | 473.363 | 331.762 | 318.021 |
| Operating Income
| 4,902.942 | 4,319.338 | 2,201.095 | 1,637.351 | 1,215.706 | 448.688 | 523.089 | 244.383 | 448.839 | -435.251 | -25.291 | -203.408 | -145.865 | 22.762 | 40.375 |
| Operating Income Ratio
| 0.289 | 0.295 | 0.174 | 0.153 | 0.133 | 0.07 | 0.081 | 0.041 | 0.081 | -0.188 | -0.038 | -0.404 | -0.274 | 0.039 | 0.067 |
| Total Other Income Expenses Net
| 199.983 | -379.126 | -331.076 | -307.764 | -223.801 | -284.984 | -312.275 | -225.123 | -143.972 | -151.556 | -185.234 | -5.741 | 113.296 | 15.384 | -15.178 |
| Income Before Tax
| 5,102.925 | 3,940.212 | 1,870.019 | 1,304.235 | 876.42 | 163.704 | 210.814 | 19.26 | 304.867 | -586.807 | 22.187 | -209.148 | -32.569 | 35.516 | 25.197 |
| Income Before Tax Ratio
| 0.301 | 0.269 | 0.148 | 0.122 | 0.096 | 0.025 | 0.033 | 0.003 | 0.055 | -0.254 | 0.034 | -0.416 | -0.061 | 0.06 | 0.042 |
| Income Tax Expense
| 997.299 | 919.455 | 466.648 | 274.584 | 198.137 | 39.616 | 161.996 | 111.805 | 143.578 | -42.559 | 10.305 | -15.914 | 5.834 | 20.465 | 22.08 |
| Net Income
| 4,105.626 | 3,020.757 | 1,403.371 | 1,026.796 | 662.807 | 99.476 | 7.685 | -134.041 | 103.949 | -442.127 | 11.882 | -193.234 | -38.403 | 15.051 | 3.117 |
| Net Income Ratio
| 0.242 | 0.206 | 0.111 | 0.096 | 0.072 | 0.015 | 0.001 | -0.023 | 0.019 | -0.191 | 0.018 | -0.384 | -0.072 | 0.026 | 0.005 |
| EPS
| 15.72 | 11.59 | 5.5 | 4.23 | 3.11 | 0.42 | 0.09 | -0.56 | 0.44 | -2.41 | -0.94 | -4.33 | -0.82 | 0.31 | 0.082 |
| EPS Diluted
| 15.67 | 11.54 | 5.47 | 4.23 | 3.11 | 0.42 | 0.09 | -0.56 | 0.44 | -2.41 | -0.94 | -4.33 | -0.82 | 0.31 | 0.082 |
| EBITDA
| 6,870.961 | 5,259.538 | 2,926.239 | 2,343.816 | 1,919.778 | 874.968 | 856.076 | 592.078 | 960.374 | -338.485 | 98.92 | -135.44 | 21.591 | 69.444 | 51.367 |
| EBITDA Ratio
| 0.405 | 0.359 | 0.234 | 0.219 | 0.196 | 0.136 | 0.13 | 0.102 | 0.174 | -0.146 | 0.15 | -0.223 | -0.065 | 0.115 | 0.086 |